Xianxiu Ji
Shanghai, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Harnessing local and system immune profiling delineating differential responders to first-line sintilimab (anti-PD-1 antibody) combined with chemotherapy in extensive-stage small cell lung cancer: an exploratory biomarker analysis of a phase II study.
Journal: Signal transduction and targeted therapy
Published: October 11, 2024
Hypoxia-Derived Exosomes Promote Lung Adenocarcinoma by Regulating HS3ST1-GPC4-Mediated Glycolysis.
Journal: Cancers
Published: January 02, 2024
Anlotinib enhanced CD8+ T cell infiltration via induction of CCL5 improves the efficacy of PD-1/PD-L1 blockade therapy in lung cancer.
Journal: Cancer letters
Published: November 22, 2023
METTL14 enhances the m6A modification level of lncRNA MSTRG.292666.16 to promote the progression of non-small cell lung cancer.
Journal: Cancer cell international
Published: August 29, 2023
HS3ST1 Promotes Non-Small-Cell Lung Cancer Progression by Targeting the SPOP/FADD/NF-κB Pathway.
Journal: BioMed research international
Published: June 16, 2022
Increased blood-based intratumor heterogeneity (bITH) is associated with unfavorable outcomes of immune checkpoint inhibitors plus chemotherapy in non-small cell lung cancer.
Journal: BMC medicine
Published: March 02, 2022
HER2-Altered Non-Small Cell Lung Cancer: Biology, Clinicopathologic Features, and Emerging Therapies.
Journal: Frontiers in oncology
Published: January 22, 2022
Special issue "The advance of solid tumor research in China": Real-world clinical outcomes of alectinib for advanced nonsmall-cell lung cancer patients with ALK fusion in China.
Journal: International journal of cancer
Published: November 02, 2021
Different clinical features between patients with ROS1-positive and ALK-positive advanced non-small cell lung cancer.
Journal: The Journal of international medical research
Published: February 15, 2021
Predictive value of unmethylated RASSF1A on disease progression in non-small cell lung cancer patients receiving pemetrexed-based chemotherapy.
Journal: Cancer biomarkers : section A of Disease markers
Published: December 17, 2019
Competitive evolution of NSCLC tumor clones and the drug resistance mechanism of first-generation EGFR-TKIs in Chinese NSCLC patients.
Journal: Heliyon
Published: June 03, 2018
Showing 1-11 of 11
Last Updated: 09/26/2026